Market Newsdesk

TAINAN, Taiwan, Dec. 09, 2020 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced a collaboration with Edge Impulse that enables the rapid development and deployment of machine learning (ML) models on the Himax HX6537-A WE-I Plus AI processor and Google TensorFlow Lite for Microcontrollers framework, allowing low-power, memory-constrained, and remote edge devices to detect complex motion, recognize sounds and classify images at sub-mW power consumption. The AI vision and sensor fusion solution is ideal for predictive maintenance, condition monitoring, asset tracking, and occupancy detection applications where power efficiency, bandwidth optimization and privacy are key requirements.

“Himax and Edge Impulse are teaming up to help developers create amazing new user experiences with secure, private, easy to use embedded development tools,” said Jordan Wu, President and Chief Executive Officer at Himax. “Offered at no charge to individual Himax developers, Edge Impulse helps simplify the creation of neural networks across a range of Himax products, including AI processors and always-on sensors, all operating at ultralow power. Edge Impulse makes it easy for embedded developers to develop TinyML models on real sensor data – from collecting data in the field to designing signal processing and ML pipelines, and to deploying models efficiently on Himax HX6537-A WE-I Plus processor with TensorFlow Lite for Microcontrollers.”

“Himax WE-I Plus and Edge Impulse end-to-end platform enable an easy TinyML development with TensorFlow on an ultralow power device,” said Pete Warden, Technical Lead of TensorFlow Lite for Microcontrollers at Google.

By using Edge Impulse and Himax, engineers can generate and export the models directly to the devices with a single button press, and in seconds, not days. These resulting inferences fully utilize the latest neural networks and Edge Impulse EON™ technology to ensure that they run as fast and energy-efficient as possible.

“The industrial, enterprise, and consumer applications of embedded ML are endless, enabling highly customizable, data-driven value for customers. Edge Impulse support for Himax AI processors and always-on vision sensors is a game changer for these markets, unlocking new value for customers by enabling ML to be embedded anywhere at extremely low-power,” said Zach Shelby, co-founder, and CEO at Edge Impulse.

On January 18th, 2021, Jan Jongboom, co-founder & CTO of Edge Impulse, and CK Hsu, senior manager of Himax will be hosting a developer webinar together, discussing TinyML and how to get started with the world’s most powerful platform for embedded developers. To learn more about Himax and Edge Impulse, register with the upcoming webinar. https://bit.ly/2IdQmde

About Himax Technologies, Inc.

Himax Technologies, Inc. (NASDAQ: HIMX) is a fabless semiconductor solution provider dedicated to display imaging processing technologies. Himax is a worldwide market leader in display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Additionally, Himax designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration (TDDI) single-chip solutions, LED driver ICs, power management ICs, scaler products for monitors and projectors, tailor-made video processing IC solutions, silicon IPs and LCOS micro-displays for augmented reality (AR) devices and heads-up displays (HUD) for automotive. The Company also offers digital camera solutions, including CMOS image sensors and wafer level optics for AR devices, 3D sensing and machine vision, which are used in a wide variety of applications such as mobile phones, tablets, laptops, TVs, PC cameras, automobiles, security, medical devices and Internet of Things. Founded in 2001 and headquartered in Tainan, Taiwan, Himax currently employs around 2,000 people from three Taiwan-based offices in Tainan, Hsinchu and Taipei and country offices in China, Korea, Japan, Israel and the US. Himax has 2,915 patents granted and 551 patents pending approval worldwide as of September 30^th, 2020. Himax has retained its position as the leading display imaging processing semiconductor solution provider to consumer electronics brands worldwide.

http://www.himax.com.tw

Forward Looking Statements

Factors that could cause actual events or results to differ materially include, but not limited to, general business and economic conditions and the state of the semiconductor industry; market acceptance and competitiveness of the driver and non-driver products developed by the Company; demand for end-use application products; reliance on a small group of principal customers; the uncertainty of continued success in technological innovations; our ability to develop and protect our intellectual property; pricing pressures including declines in average selling prices; changes in customer order patterns; changes in estimated full-year effective tax rate; shortages in supply of key components; changes in environmental laws and regulations; exchange rate fluctuations; regulatory approvals for further investments in our subsidiaries; our ability to collect accounts receivable and manage inventory and other risks described from time to time in the Company’s SEC filings, including those risks identified in the section entitled “Risk Factors” in its Form 20-F for the year ended December 31, 2019 filed with the SEC, as may be amended.

Company Contacts:

Eric Li
, C
hief IR/PR Officer

Himax Technologies, Inc.
Tel: +886-6-505-0880 Ext. 60145
Fax: +886-2-2314-0877
Email: [email protected]
www.himax.com.tw

Karen Tiao
, Investor Relations

Himax Technologies, Inc.
Tel: +886-2-2370-3999 Ext. 22326
Fax: +886-2-2314-0877
Email: [email protected]
www.himax.com.tw 

• The
  CLI
  study
  is unlikely to meet
  its
  primary endpoint by the time of the final analysis
• Substantial low number of events in the placebo group
  in the
  CLI
  study
  decreased the statistical power of the
  study to meet its primary endpoint
• PLX
  -PAD was well tolerated, and
  n
  o safety concerns were raised
• Company to
  terminate
  the
  CLI
  study to
  focus
  on
  different therapeutic areas
  in its pipeline
  and
  expect
  s
  three clinical readouts within the coming calendar year
• Company will
  host
  conference call on
  December 9, 2020, at
  8
  :
  30
  AM ET / 3
  :
  30
  PM Israel time
  

HAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today announced that the independent Data Monitoring Committee (DMC) of its global pivotal Phase III study for the treatment of critical limb ischemia (CLI) issued its recommendation letter following the interim analysis. The clinical dataset was reviewed by the independent DMC for safety and analysis of the primary endpoint of amputation-free survival, defined as time to occurrence of major amputation of the index leg or death.

Based on the review, the DMC concluded that the CLI study is unlikely to meet the primary endpoint by the time of the final analysis. The DMC advised the Company that the CLI study population has experienced a substantial low number of events (major amputation of the index leg or death), different from what is known in clinical medicine for the rate of these events in this patient population. The lower than anticipated event rate in the placebo group reduced the statistical power of the study to meet its primary endpoint.

DMC noted that PLX-PAD was well tolerated, and no significant safety concerns were raised during the study.

Following the DMC’s recommendation, the Company decided to terminate the CLI study. Currently, the Company continues to be blinded to the CLI study clinical data.

“We are deeply disappointed by the outcome of the CLI interim analysis. In light of the DMC’s recommendation, we decided that it would be in the best interests of the Company and its shareholders to terminate the CLI study and focus our resources and efforts on our other lead indications,” stated Pluristem CEO and President, Yaky Yanay.

“We expect to present topline clinical results during calendar year 2021, including our Phase III study in muscle regeneration following hip fracture, Phase II studies in Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 and our Phase I study in incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Pluristem is well positioned to advance and support future development of these indications.”

“Throughout the years, we have developed unique and propriety expertise, knowhow and intellectual property, alongside a diverse clinical pipeline and we possess a state-of-the-art cell manufacturing facility. We believe our platform and technology will be a meaningful force in regenerative medicine in a variety of therapeutic areas,” Mr. Yanay concluded.

The Company will host a conference call on December 9, 2020 at 8:30AM ET / 3:30PM Israel time. It can be accessed via:

https://webcasting.brrmedia.co.uk/broadcast/5fc769bd2ac82b2af52e277b

About
Pluristem
Therapeutics

Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company’s proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses that it expects topline clinical results during the calendar year 2021 with respect to its Phase III study in muscle regeneration following hip fracture, its Phase II studies in ARDS associated with COVID-19 and its Phase I study in incomplete hematopoietic recovery following HCT, its belief that it is well positioned to support the future development of these indications and its belief that its platform and technology will be a meaningful force in regenerative medicine in a variety of therapeutic areas. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristem’s products may not be approved by regulatory agencies, Pluristem’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristem’s process; Pluristem’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristem’s patents may not be sufficient; Pluristem’s products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem’s reports filed from time to time with the Securities and Exchange Commission.

Contact:

Dana Rubin
Director of Investor Relations
972-74-7107194
[email protected]  

WASHINGTON, Dec. 09, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced continued global investment in its Data & Analytics practice within the Forensic and Litigation Consulting segment with the appointment of Richard Chalk and Yuval Saban as Senior Managing Directors.

Mr. Chalk, who is based in London, is a recognized expert providing data and analytics advice around business-critical events. These include financial crime and compliance investigations, litigation, valuation disputes, and other distressed circumstances. He drives the use of innovative technology and analytics to resolve some of the most complex issues challenging FTI Consulting’s clients. His main areas of expertise include complex data analytics and large-scale sanctions/anti-money laundering (“AML”) investigations, where he has represented clients before European and U.S. regulators and courts.

Mr. Saban, who is based in New York, leads the collaboration among business domain experts, digital technologists, data science practitioners, and engineers and developers through the design, development and launch of highly transformative solutions. He has led large-scale, multimillion-dollar artificial intelligence-centered business and digital transformation engagements and is focused on machine-learning, advanced scientific computing methods, analytics, risk management, and business transformation.

Commenting on the appointments, Paul Ficca, Global Segment Leader of the Forensic and Litigation Consulting segment at FTI Consulting, said, “The application of data analytics underpins all global investigations and large-scale disputes, and we continue to invest in talent to help corporates and law firms manage their most significant and complex matters. Richard and Yuval are both highly regarded within the market, bringing a wide range of experience in data-driven situations that add to our depth of talent.”

Mr. Chalk returns to FTI Consulting, where he began his consulting career. He has significant global financial services experience and continues to be involved in addressing thematic industry issues, often working alongside legal counsel. He was recognized in the Who’s Who Legal: Consulting Experts 2020 guide for his forensic work on major AML-related cases for global financial institutions and for the expert data analysis he provides in high-profile investigations.

Mr. Saban joins FTI Consulting from IBM, where he focused on the financial services sector. His clients included national and regional U.S. banks, insurance and supplemental insurance groups, wealth management, and healthcare insurers.

About FTI Consulting

FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 6,200 employees located in 28 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $2.35 billion in revenues during fiscal year 2019. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn.

FTI Consulting, Inc.

555 12^th Street NW
Washington, DC 20004
+1.202.312.9100

Investor
Contact
:

Mollie Hawkes
+1.617.747.1791
[email protected]

Media
Contact
:

Matthew Bashalany
+1.617.897.1545
[email protected]

 

EDMONTON, Alberta, Dec. 09, 2020 (GLOBE NEWSWIRE) — Canadian-based startup, AlphaPhenomics announced this week that it has developed and commenced sales of proprietary hardware and software solutions for the non-invasive biometric measurement of livestock. The Company has developed easy-to-use, cost effective, low maintenance hardware to capture and analyze scanned images through its 2D / 3D / 4D multispectral camera. These cameras operate autonomously and are able to capture images 24/7 in real-time. Over the last several years, the Company has secured considerable IP and a comprehensive library of patents related to the hardware, firmware and software within its product portfolio.

“AlphaPhenomics is fully committed to bringing the protein production industry into a new era of even higher efficiency and productivity,” stated Dr. Jack Behan, the Company’s Chief Executive Officer. “We are able to produce simple output solutions based on the images captured, collected by our hardware which are then data mined using machine learning software that look at the interrelationships with other stored historic data to assist in more accurate outcome predictions. This is all achieved non-invasively; we are committed to the strongest level of animal welfare whilst comprehensively improving sustainable productivity.”

AlphaPhenomics state-of-the-art technology can be applied across multiple sectors; animal breeding, reproduction, agriculture, bio-security / bio-surveillance and veterinary supervision, to name a few. The images are captured in 3D format, with multispectral potential to capture images in microwave, infra-red along with 4D video format. Using encrypted block-chain technology, the highly compressed data is sent wirelessly to central servers for biometric data processing.

The Company continues to develop solutions that will allow real-time assessment of a number of applications to assist in more accurate outcome predictions. In addition, metabolic surveillance can serve as an early warning system for the prediction of disease and viral or bacterial infections. Additional information about these programs will be disclosed in the coming months. AlphaPhenomics continues to pursue additional opportunities for pipeline expansion.

About AlphaPhenomics, Inc.

AlphaPhenomic’s mission is to be the leading precision livestock partner by providing a fully integrated image and data capture, and analytics platform, to our customers in the precision agriculture, disease bio-surveillance and data driven sustainable livestock farming sector.

Our digital biotechnology platform, IMAGENOMICS, enables our customers to increase productivity, improve yield, and lower production costs through the use of our proprietary real-time, non-invasive, full body bio metrics technology and phenotypic data capture.

Interested parties can learn more about at www.alphaphenomics.com

Investor or Media Inquiries:

Dr. Jack Behan
CEO, AlphaPhenomics
[email protected]
+44 7500 878269

Jacksonville, Florida, Dec. 09, 2020 (GLOBE NEWSWIRE) — BOTS, Inc. (OTC: BTZI), an emerging innovator of products, technologies, and services for the rapidly growing cyber-security, digital robotics automation and AI for manufacturing industries, CEO discusses and outlines the company’s strategy for 2021.

Paul Rosenberg, BOTS INC., CEO begins the announcement by stating: “With the recent changes in our business model over the past couple of months, we want to take this opportunity to thank our investors and shareholders for both your investments and ongoing support of our company. I feel it is important for us to continue making the market aware of our current projects and our strategic agenda for 2021 and well into the future.”

The company has been very quiet these past few months as our business integration with First Bitcoin Capital LLC., was unfortunately not as smooth as we had hoped it would be. This resulted in the delay of Bots Inc. posting its financial results. However, we are working on the completion of our 1^st and 2^nd Quarter financials for the company’s 2021 Fiscal Year. Therefore, the company will be current in its financial reporting shortly.

During these last few months, the company has signed an agreement with Cyber Security Group LLC. to create a JV between the two companies. A joint company will be operating under the name; Bots International Inc.

A few updates regarding Bots International Inc.; we have completed the construction of a comprehensive security system for the SFOR.TRADE cryptocurrency exchange, which, once transferred to a more powerful server base and updated its technical component, will be able to provide customers with stable and fast operation at the same level as the largest cryptocurrency exchanges in the world. SFOR.TRADE will be launched this coming week.

Bots International Inc. has also expanded Web Application Firewall (WAF) services platform with industry-leading capabilities to protect web applications, speed application deployments, and reduce application security costs.

Now the Web Application Firewall is more capable of leveraging its security efficacy to protect against advanced layer 7 attacks (such as those based on geolocation, DDoS, SQL injection, zero-day threats, AJAX applications, JSON payloads, OWASP Top Ten, and others) in a convenient, local and cloud-based service.

In addition, WAF solutions offer automated, self-learning capabilities in a highly customizable framework to rapidly respond and adapt to evolving threats, with quick WAF implementation and unified, scalable policy enforcement capabilities.

Bots International Inc. leading WAF services will be offered in both on-premises and subscription-based cloud offerings. The company’s versatile, easy to deploy WAF solutions let organizations confidently incorporate local and cloud resources while protecting apps and data from increasingly sophisticated security attacks, risks, and vulnerabilities.

WAF solution is only one of many products that the company will be offering to its corporate clients. There will be more announcements to come on this in the next few weeks.

We have also developed a cryptocurrency trading bot that is simple and intuitive for crypto beginners to setup and run.

The 24/7 open hours of the crypto market has necessitated the use of trading automation for investors that are involved in trading cryptocurrencies. CryptoBot will be an additional tool that crypto investors will use when trading on exchange SFOR.TRADE

Bots Inc. owns the rights to U.S. Patent No. 9,135,787 – (Bitcoin Kiosk / ATM Device and System Integrating Enrollment Protocol and Method of Using the Same). Known as the “Bitcoin ATM patent” this patent is related to the purchase and sale of cryptocurrencies utilizing a Bitcoin ATM or kiosk that allows customers to purchase Bitcoin or other cryptocurrencies by using cash, debit or credit cards.

Bitcoin ATMs do not require their users to have bank accounts, so customers can simply pay and instantly buy or sell Bitcoin, or other cryptocurrencies.

The United States still houses a significant percentage of all the Bitcoin ATMs installed globally. According to Coinatmradar, cryptocurrency ATMs have been installed in 9,187 locations in the US (https://coinatmradar.com)

All Bitcoin ATMs and Kiosks manufactured and sold in the U.S., and all Bitcoin ATMs and Kiosks operated in the U.S. are believed to be subject to this patent and the company intends to enforce its patent rights.

Our business model also includes ownership positions in other publicly traded companies. We have large positions in companies such as: Kronos Advanced Technologies, Inc., and Obitx Inc. These are start-up companies with what we feel to be great potential.

“In conclusion, I would like to say, that it has been a difficult year for many companies due to the global pandemic. At the beginning of this year, management decided to completely change our direction, and sector by transitioning into a technology company complete with a new corporate look. We knew this would not be an easy move, but it was the right move for the long-term success of the company. Again, I would like to sincerely thank BOTS shareholders for your ongoing support.”  – Paul Rosenberg, CEO

About BOTS, Inc.

Headquartered in San Juan, Puerto Rico, BOTS, Inc., a publicly traded OTC Markets innovator trading under the symbol (BTZI) – is a diversified company developing and servicing blockchain and robotics solutions for its clientele. The Company is committed to driving the innovations needed to shape the future of digital robotic automation management through digital technology and decentralized blockchain solutions. Management is dedicated to the strong growth of Distributed Asset Technology and Robotic Process Automation (RPA).

Shareholders, potential investors, and others should note that we announce material events and material financial information to our shareholders and the public using our website and the social media addresses listed below, as well as in our SEC filings, press releases, public conference calls, and webcasts. We also use social media to communicate with our subscribers and the public about our Company, our services, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage shareholders, the media, and others interested in our Company to review the information we post on the U.S. social media channels listed below. This list may be updated from time to time.

Track BTZI news on Facebook @ https://www.facebook.com/Bots.Bz/

Follow BTZI news on Twitter @Bots_bz http://www.Twitter.com/Bots_bz

Find BTZI news at http://www.bots.bz

Bots, Inc. has been featured in media nationwide, including CNBC, Bloomberg, TheStreet.com.

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as may be disclosed in the Company’s filings. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release. Such forward-looking statements are risks that are detailed in the Company’s website and filings.

Contact:

Paul Rosenberg, CEO

[email protected]

SHANGHAI, China, Dec. 09, 2020 (GLOBE NEWSWIRE) — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating Trodelvy^TM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC).

EVER-132-002 is a Phase 3 Asian study designed to assess and compare the efficacy and safety of sacituzumab govitecan versus TPC in Asian patients with HR+/HER2- mBC who received at least two, and no more than four systemic chemotherapy regimens. The trial will enroll up to 330 HR+/HER2- mBC patients in China mainland, Taiwan and South Korea. The primary endpoint is progression free survival (PFS) per RECIST v 1.1 by an Independent Review Committee.

“HR+/HER2- breast cancer is the most prevalent subtype of breast cancer and accounts for more than 60% of all breast cancer cases. There is a significant unmet need for new treatment options for women with HR+/HER2− mBC who have failed initial standard-of-care chemotherapies,” said Dr. Yang Shi, Chief Medical Officer for Oncology at Everest Medicines. “The clinical data generated to date suggested promising clinical activity of sacituzumab govitecan in HR+/HER2− mBC patients who have failed at least two chemotherapy regimens. We are very excited to initiate our Phase 3 registration trial as we believe sacituzumab govitecan has tremendous potential to become the new standard of care in patients with pre-treated HR+/HER2− mBC.”

Immunomedics (now part of Gilead Sciences, Inc), which developed sacituzumab govitecan, is currently recruiting patients for the TROPiCS-02 trial, an open-label, randomized, multi-center Phase 3 study to compare the efficacy and safety of sacituzumab govitecan versus the TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- mBC, after failure of at least two, and no more than four, prior chemotherapy regimens for metastatic disease.

About Sacituzumab Govitecan

Sacituzumab govitecan is a first-in-class antibody-drug conjugate (ADC) directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. Sacituzumab govitecan was granted accelerated approval by the U.S. FDA in April 2020 for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. In September 2020 at the ESMO2020 annual conference, Immunomedics (now part of Gilead Sciences, Inc.) presented the confirmatory Phase 3 trial results (ASCENT) demonstrating that sacituzumab govitecan significantly improved progression free survival (PFS) and overall survival (OS) over standard single agent chemotherapy in pre-treated metastatic triple-negative breast cancer (mTNBC) patients with a hazard ratio of 0.41 and 0.48 respectively. Under a licensing agreement with Immunomedics, Everest Medicines has exclusive rights to develop, register, and commercialize sacituzumab govitecan for all cancer indications in Greater China, South Korea, and certain Southeast Asian countries.

In October 2020, sacituzumab govitecan was included in the updated 2020 Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China, compiled by the Breast Cancer Expert Committee of the National Cancer Control Center, the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association, and the Cancer Drug Clinical Research Professional Committee of the Chinese Anti-Cancer Association.

About
HR+/HER2- Breast Cancer

Hormone Receptor Positive, HER2 Negative (HR+/HER2-) breast cancer is the most common form of breast cancer in China, representing over 60% of all breast cancer cases. This subtype of breast cancer grows in connection with estrogen or progesterone and is likely to respond to hormone therapies initially, but almost all HR+/HER2- metastatic breast cancers become refractory over time.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. Everest Medicines obtained the development and commercial right in greater China, South Korea and certain Southeast Asian countries of sacituzumab govitecan from Immunomedics in April 2019. For more information, please visit its website at www.everestmedicines.com.

Everest Medicines

Media in US and Europe:
Darcie Robinson
Vice President
Westwicke PR
(203) 919-7905
[email protected]

Media in China:
Edmond Lococo
Managing Director
ICR Asia
+86 (10) 6583-7510
[email protected]

 

TOKYO, Dec. 09, 2020 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) has launched a new high-speed CMOS image capture module for its T2000 test platform that enables highly parallel, 64-site testing of both D-PHY and C-PHY devices for the rapidly growing smart phone market. The new T2000 4.8-Gbps CMOS image capture module, known as the 4.8GICAP, is designed to efficiently transfer data from CMOS image sensors (CIS) to the T2000 tester’s high-performance image processor engine (IPE). It is the first mass-produced test solution to achieve a maximum data rate of 3.5 Gsps for advanced C-PHY version 1.2 devices as well as the industry’s fastest capture speed of 4.8 Gbps for D-PHY version 2.1 devices. 

An estimated 75% of CIS devices produced today are used in smart phone cameras. With the latest smart phones incorporating multiple cameras, CIS production is forecasted to grow approximately 41% over the next four years, according to an Advantest study. In addition, the latest CIS devices have high resolution on the order of 100 million pixels. These factors increase demand for test solutions that can handle larger volumes of data than ever before while operating at higher speeds to cost-effectively serve the rapidly expanding smart phone market.

The 4.8GICAP module, combined with Advantest’s 3rd generation IPE, can simultaneously capture images and transfer data to the IPE using a two-bank memory mechanism. This will significantly reduce test time.

The unit is designed for installation on the T2000 ISS tester with a fully compatible test program, prober, light source and device interface. This combination produces CIS measurement tools capable of 64-site parallel testing, which supports latest C-PHY in addition to the MIPI standard D-PHY. The new module delivers industry-leading performance with high-speed transmission lines.

The versatile T2000 test platform enables users to respond quickly to shifting market needs with minimal capital investment while also helping to reduce development times for new designs. Its modular architecture is ideally suited to accommodate new generations of devices.

“By providing a measurement environment that can handle greater data-transfer volumes and faster CIS devices, we are bringing improved cost efficiencies to the smart phone camera market,” said Toshiaki Adachi, vice president of the T2000 Business Unit at Advantest.

The 4.8GICAP module has begun shipping to several key customers.

For more information on the T2000 test platform, visit https://www.advantest.com/products/ic-test-systems/t2000.

About Advantest Corporation

Advantest (TSE: 6857) is the leading manufacturer of automatic test and measurement equipment used in the design and production of semiconductors for applications including 5G communications, the Internet of Things (IoT), autonomous vehicles, artificial intelligence (AI), machine learning, smart medical devices and more. Its leading-edge systems and products are integrated into the most advanced semiconductor production lines in the world. The company also conducts R&D to address emerging testing challenges, produces multi-vision metrology scanning electron microscopes essential to photomask manufacturing, and offers groundbreaking 3D imaging and analysis tools. Founded in Tokyo in 1954, Advantest is a global company with facilities around the world and an international commitment to sustainable practices and social responsibility. More information is available at www.advantest.com.

ADVANTEST CORPORATION 
3061 Zanker Road
San Jose, CA 95134, USA
Tish Kelly-Mick
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3b8b0ced-151f-4cfd-8f48-715b3cf38cbb